rebranding – Talk Bio

bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout

1 month ago talkbio0Tagged Anemia, Sickle Cell, Bluebird Bio, Capital Partners, Carlyle, Cerebral Adrenoleukodystrophy, commercial, David Meek, DKK1 gene, execution, FDA-approved therapies, gene therapy, Genetix Biotherapeutics, Investments, Manufacturing, Private Equity, rebranding, Thalassemia

bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment

FogPharma Rebrands to Parabilis Medicines, Emphasizing AI-Driven Drug Discovery

12 months ago talkbio0Tagged Artificial Intelligence, capabilities, Drug Discovery, FogPharma, Parabilis Medicines, rebranding

FogPharma, Parabilis Medicines, AI capabilities, drug discovery, rebranding

Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals

1 year ago talkbio0Tagged Adult, Aeterna Zentaris, Biological Factors, Biopharma, Changing, COSCIENS, development aspects, Diagnostic tests, Macrilen, rebranding, Somatotropin deficiency

Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency